

10/525096

BT01 Rec'd PCT/PT 22 FEB 2005

L1 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1993:531551 CAPLUS <<LOGINID::20050210>>

DN 119:131551

TI Therapeutics for excessive collagen formation

IN Myata, Hiroshi; Komatsu, Hidetada; Hamano, Shuichiro; Kikuchi, Shinji;

Ichikawa, Kyoshi; Arai, Nobuhiko

PA Kissei Pharmaceutical, Japan

SO Jpn. Kokai Tokkyo Koho, 8 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 05163222	A2	19930629	JP 1991-361079	19911218 <--
PRAI JP 1991-361079		19911218		

AB Tranilast or its pharmacol. acceptable salts are useful for treatment of diseases (e.g. keloid) caused by excess collagen formation. Tranilast at 50-200 mg/kg p.o. inhibited the formation of carrageenan-induced granulation tissue in rats in a dose-dependent manner. Powders were formulated containing 100 g tranilast and 900 g lactose.